Biogen Idec Press Releases - PRWeb Press Release Group http://www.prweb.com Biogen Idec Press Releases - Powered by PRWeb en xml@emediawire.com xml@emediawire.com 30 New Study: Avonex®, The Most Prescribed Multiple Sclerosis Treatment Worldwide, Demonstrates Superior Adherence http://www.prweb.com/releases/2006/09/prweb444346.htm Biogen Idec today announced findings today from the Global Adherence Project (GAP) that demonstrated that patients taking AVONEX® (interferon beta-1a) adhered to therapy more than patients taking other approved disease modifying therapies (DMTs) included in the study. The GAP study found that patients taking AVONEX had statistically significant higher adherence rates than the other DMTs. Additionally, the study showed that adherent patients reported better quality of life, less cognitive impairment and fewer problems with injection site reactions that non-adherent patients. (PRWeb Sep 29, 2006)

Read the full story at http://www.prweb.com/releases/2006/09/prweb444346.htm

]]> Fri, 29 Sep 2006 07:00:00 GMT http://www.prweb.com/releases/2006/09/prweb444346.htm